GOP Representative Lawler Labels Marijuana a 'Gateway Drug' While Opposing Trump's Rescheduling Proposal

Written by Emily J. Thompson, Senior Investment Analyst

Source: SeekingAlpha

Updated: Dec 16 2025

0mins

Source: SeekingAlpha

Lawmaker's Concerns: Rep. Mike Lawler (R-N.Y.) expressed concerns about President Trump's potential plan to reschedule marijuana, labeling it a "gateway drug" and highlighting the increased THC levels in modern cannabis compared to decades ago.
Trump's Executive Order: President Trump confirmed he is considering an Executive Order to move marijuana from Schedule I to Schedule III under the Controlled Substances Act.
Market Reaction: Following the news, cannabis multi-state operators saw significant gains in trading, with companies like Ascend Wellness and Curaleaf Holdings among those benefiting.
Investment Insights: The article mentions various cannabis ETFs and provides insights into the performance of companies like Curaleaf and Trulieve, suggesting potential investment opportunities amidst market volatility.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.